

Application No. 09/750,609

II	18-32, 40-50, 68	Oligonucleotides, a kit and an isolated nucleic acid, vector and recombinant host cell, including SEQ ID Nos. 3-4, 13-14 and 32-34.
III	33-36, 51, 59-64	An isolated and purified biologically active human NE transporter polypeptide, including SEQ ID Nos. 2-4, 12-14.
IV	37-38, 54-57	An isolated and purified antibody and method of producing the same, including SEQ ID Nos. 2-4, 12-14.
V	39	A hybridoma cell line, including SEQ ID Nos. 2-4, 12-14.
VI	52-53, 71-79	A method of detecting RNA and DNA and a method to enhance transport of NE and detection of impaired NE transport, including SEQ ID Nos. 1-2, 11-14, and 32-34.
VII	58	A method of detecting polypeptide, including SEQ ID Nos. 3-4, 13-14 and 32-34.
VIII	65-66	A method of detecting antibody, including SEQ ID Nos. 3-4, 13-14 and 32-34.
IX	69-70	A transgenic non-human animal, including SEQ ID Nos. 3-4, 13-14 and 32-34.

APPLICANTS' ELECTION

Applicants hereby elect the invention of Group I, claims 1 through 17, drawn to a method of screening for susceptibility to sub-optimal norepinephrine (NE) transport in a subject, including using SEQ ID Nos. 9-10 for prosecution at this time.

REMARKS

Claims 1-79 are now pending in the subject U.S. patent application. Claims 1-79 as filed have been subjected to a Restriction/Election Requirement.

In response to the Restriction/Election Requirement, applicants have elected the claims of Group I, claims 1 – 17, for prosecution at this time.